William Dougall

William Dougall

UNVERIFIED PROFILE

Are you William Dougall?   Register this Author

Register author
William Dougall

William Dougall

Publications by authors named "William Dougall"

Are you William Dougall?   Register this Author

65Publications

1576Reads

40Profile Views

Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).

Authors:
Elizabeth Ahern Annette Cubitt Emma Ballard Michele W L Teng William C Dougall Mark J Smyth David Godbolt Rishendran Naidoo Amanda Goldrick Brett G M Hughes

Trials 2019 Dec 19;20(1):753. Epub 2019 Dec 19.

School of Medicine, University of Queensland, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1186/s13063-019-3951-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924018PMC
December 2019

Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.

Authors:
William C Dougall Amelia Roman Aguilera Mark J Smyth

Clin Transl Immunology 2019 27;8(10):e01081. Epub 2019 Sep 27.

Immunology in Cancer and Infection Laboratory QIMR Berghofer Medical Research Institute Herston Qld Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cti2.1081DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6763724PMC
September 2019

CD96 Is an Immune Checkpoint That Regulates CD8 T-cell Antitumor Function.

Authors:
Deepak Mittal Ailin Lepletier Jason Madore Amelia Roman Aguilera Kimberley Stannard Stephen J Blake Vicki L J Whitehall Cheng Liu Mark L Bettington Kazuyoshi Takeda Georgina V Long Richard A Scolyer Ruth Lan Nathan Siemers Alan Korman Michele W L Teng Robert J Johnston William C Dougall Mark J Smyth

Cancer Immunol Res 2019 04 20;7(4):559-571. Epub 2019 Mar 20.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2326-6066.CIR-18-0637DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445751PMC
April 2019

The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumor-infiltrating T cells.

Authors:
Ailin Lepletier Viviana P Lutzky Deepak Mittal Kimberley Stannard Thomas S Watkins Champa N Ratnatunga Corey Smith Helen M McGuire Roslyn A Kemp Pamela Mukhopadhyay Nicola Waddell Mark J Smyth William C Dougall John J Miles

Immunol Cell Biol 2019 02 17;97(2):152-164. Epub 2018 Oct 17.

QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.

View Article

Download full-text PDF

 Source
http://doi.wiley.com/10.1111/imcb.12205
Publisher Site
http://dx.doi.org/10.1111/imcb.12205DOI Listing
February 2019

Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma.

Authors:
André Steven Sandra Leisz Sebastian Fussek Behdokht Nowroozizadeh Jiaoti Huang Daniel Branstetter William C Dougall Martin Burchardt Arie S Belldegrun Barbara Seliger Allan Pantuck Nils Kroeger

Urol Oncol 2018 11 28;36(11):502.e15-502.e24. Epub 2018 Aug 28.

Department of Urology, University Medicine at the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany; Institute of Urologic Oncology, Department of Urology, David Geffen School of Medicine at the University of California, Los Angeles, CA; Institute of Medical Biochemistry and Molecular Medicine, University Medicine at the Ernst-Moritz-Arndt University Greifswald, Greifswald, Germany. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.urolonc.2018.07.013DOI Listing
November 2018

Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy.

Authors:
Elizabeth Ahern Mark J Smyth William C Dougall Michele W L Teng

Nat Rev Clin Oncol 2018 11;15(11):676-693

Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://www.nature.com/articles/s41571-018-0095-y
Publisher Site
http://dx.doi.org/10.1038/s41571-018-0095-yDOI Listing
November 2018

TIGIT immune checkpoint blockade restores CD8 T-cell immunity against multiple myeloma.

Authors:
Camille Guillerey Heidi Harjunpää Nadège Carrié Sahar Kassem Tricia Teo Kim Miles Sophie Krumeich Marianne Weulersse Marine Cuisinier Kimberley Stannard Yuan Yu Simone A Minnie Geoffrey R Hill William C Dougall Hervé Avet-Loiseau Michele W L Teng Kyohei Nakamura Ludovic Martinet Mark J Smyth

Blood 2018 10 9;132(16):1689-1694. Epub 2018 Jul 9.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2018-01-825265DOI Listing
October 2018

An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.

Authors:
Alexander Liede Rohini K Hernandez Sally W Wade Ronghai Bo Nathan C Nussbaum Elizabeth Ahern William C Dougall Mark J Smyth

Oncoimmunology 2018 5;7(12):e1480301. Epub 2018 Sep 5.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/2162402X.2018.1480301DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279336PMC
September 2018

CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.

Authors:
Xian-Yang Li Indrajit Das Ailin Lepletier Venkateswar Addala Tobias Bald Kimberley Stannard Deborah Barkauskas Jing Liu Amelia Roman Aguilera Kazuyoshi Takeda Matthias Braun Kyohei Nakamura Sebastien Jacquelin Steven W Lane Michele Wl Teng William C Dougall Mark J Smyth

J Clin Invest 2018 06 14;128(6):2613-2625. Epub 2018 May 14.

Immunology in Cancer and Infection Laboratory and.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1172/JCI98769DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983325PMC
June 2018

Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.

Authors:
Heidi Harjunpää Stephen J Blake Elizabeth Ahern Stacey Allen Jing Liu Juming Yan Viviana Lutzky Kazuyoshi Takeda Amy Roman Aguilera Camille Guillerey Deepak Mittal Xian Yang Li William C Dougall Mark J Smyth Michele W L Teng

Oncoimmunology 2018 26;7(7):e1445949. Epub 2018 Mar 26.

Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/2162402X.2018.1445949DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993492PMC
March 2018

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Authors:
Amelia Roman Aguilera Viviana P Lutzky Deepak Mittal Xian-Yang Li Kimberley Stannard Kazuyoshi Takeda Günter Bernhardt Michele W L Teng William C Dougall Mark J Smyth

Oncoimmunology 2018 1;7(5):e1424677. Epub 2018 Feb 1.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
https://www.tandfonline.com/doi/full/10.1080/2162402X.2018.1
Publisher Site
http://dx.doi.org/10.1080/2162402X.2018.1424677DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927540PMC
February 2018

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.

Authors:
Elizabeth Ahern Heidi Harjunpää Jake S O'Donnell Stacey Allen William C Dougall Michele W L Teng Mark J Smyth

Oncoimmunology 2018 14;7(6):e1431088. Epub 2018 Feb 14.

Department of Immunology, Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1080/2162402X.2018.1431088DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980384PMC
February 2018

Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method.

Authors:
Clive R Taylor Daniel Branstetter Edward Manna William C Dougall Jeanine Bussiere Carol W Johnson

Appl Immunohistochem Mol Morphol 2017 May/Jun;25(5):299-307

*Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles ‡Dako, an Agilent technologies company, Carpinteria ∥Department of Comparative Biology and Safety Sciences ¶Formerly Department of Pathology, Amgen Inc., Thousand Oaks, CA †Formerly Department of Pathology §Department of Oncology Research, Amgen Inc., Seattle WA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/PAI.0000000000000503DOI Listing
November 2017

Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.

Authors:
Elizabeth Ahern Heidi Harjunpää Deborah Barkauskas Stacey Allen Kazuyoshi Takeda Hideo Yagita David Wyld William C Dougall Michele W L Teng Mark J Smyth

Clin Cancer Res 2017 Oct 20;23(19):5789-5801. Epub 2017 Jun 20.

Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-0606DOI Listing
October 2017

RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.

Authors:
Shuan Rao Verena Sigl Reiner Alois Wimmer Maria Novatchkova Alexander Jais Gabriel Wagner Stephan Handschuh Iris Uribesalgo Astrid Hagelkruys Ivona Kozieradzki Luigi Tortola Roberto Nitsch Shane J Cronin Michael Orthofer Daniel Branstetter Jude Canon John Rossi Manolo D'Arcangelo Johan Botling Patrick Micke Linnea La Fleur Karolina Edlund Michael Bergqvist Simon Ekman Thomas Lendl Helmut Popper Hiroshi Takayanagi Lukas Kenner Fred R Hirsch William Dougall Josef M Penninger

Genes Dev 2017 10 8;31(20):2099-2112. Epub 2017 Nov 8.

Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA), Vienna 1030, Austria.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1101/gad.304162.117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733500PMC
October 2017

Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Authors:
Monica E Reyes Takeo Fujii Daniel Branstetter Savitri Krishnamurthy Hiroko Masuda Xiaoping Wang James M Reuben Wendy A Woodward Beatrice J Edwards Gabriel N Hortobagyi Debu Tripathy William C Dougall Bedrich L Eckhardt Naoto T Ueno

Breast Cancer Res Treat 2017 Jul 17;164(1):57-67. Epub 2017 Apr 17.

Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/10.1007/s10549-017-4233-5
Publisher Site
http://dx.doi.org/10.1007/s10549-017-4233-5DOI Listing
July 2017

TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.

Authors:
William C Dougall Sema Kurtulus Mark J Smyth Ana C Anderson

Immunol Rev 2017 03;276(1):112-120

Evergrande Center for Immunologic Diseases and Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/imr.12518DOI Listing
March 2017

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.

Authors:
Stephen J Blake William C Dougall John J Miles Michele W L Teng Mark J Smyth

Clin Cancer Res 2016 Nov 12;22(21):5183-5188. Epub 2016 Sep 12.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0933DOI Listing
November 2016

RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation.

Authors:
Guillermo Yoldi Pasquale Pellegrini Eva M Trinidad Alex Cordero Jorge Gomez-Miragaya Jordi Serra-Musach William C Dougall Purificación Muñoz Miguel-Angel Pujana Lourdes Planelles Eva González-Suárez

Cancer Res 2016 10 1;76(19):5857-5869. Epub 2016 Aug 1.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/0008-5472.CAN-15-2745DOI Listing
October 2016

RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.

Authors:
Emma Nolan François Vaillant Daniel Branstetter Bhupinder Pal Göknur Giner Lachlan Whitehead Sheau W Lok Gregory B Mann Kathy Rohrbach Li-Ya Huang Rosalia Soriano Gordon K Smyth William C Dougall Jane E Visvader Geoffrey J Lindeman

Nat Med 2016 08 20;22(8):933-9. Epub 2016 Jun 20.

ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research (WEHI), Parkville, Victoria, Australia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/nm.4118DOI Listing
August 2016

Rankl Impairs Lactogenic Differentiation Through Inhibition of the Prolactin/Stat5 Pathway at Midgestation.

Authors:
Alex Cordero Pasquale Pellegrini Adrián Sanz-Moreno Eva M Trinidad Jordi Serra-Musach Chetan Deshpande William C Dougall Miguel Angel Pujana Eva González-Suárez

Stem Cells 2016 Apr 13;34(4):1027-39. Epub 2016 Jan 13.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/stem.2271DOI Listing
April 2016

Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.

Authors:
Maria M Szwarc Ramakrishna Kommagani Allison P Jacob William C Dougall Michael M Ittmann John P Lydon

PLoS One 2015 10;10(6):e0128467. Epub 2015 Jun 10.

Department of Molecular Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas, United States of America.

View Article

Download full-text PDF

 Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0128467PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464738PMC
March 2016

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers.

Authors:
Martin Widschwendter Matthew Burnell Lindsay Fraser Adam N Rosenthal Sue Philpott Daniel Reisel Louis Dubeau Mark Cline Yang Pan Ping-Cheng Yi D Gareth Evans Ian J Jacobs Usha Menon Charles E Wood William C Dougall

EBioMedicine 2015 Oct 9;2(10):1331-9. Epub 2015 Sep 9.

Therapeutic Innovation Unit (TIU), Amgen Inc., Seattle, WA 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ebiom.2015.08.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634624PMC
October 2015

RANK and RANK ligand expression in primary human osteosarcoma.

Authors:
Daniel Branstetter Kathy Rohrbach Li-Ya Huang Rosalia Soriano Mark Tometsko Michelle Blake Allison P Jacob William C Dougall

J Bone Oncol 2015 Sep 29;4(3):59-68. Epub 2015 Jul 29.

Therapeutic Innovation Unit, Amgen Inc., Seattle, WA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jbo.2015.06.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986823PMC
September 2015

RANK-ligand (RANKL) expression in young breast cancer patients and during pregnancy.

Authors:
Hatem A Azim Fedro A Peccatori Sylvain Brohée Daniel Branstetter Sherene Loi Giuseppe Viale Martine Piccart William C Dougall Giancarlo Pruneri Christos Sotiriou

Breast Cancer Res 2015 Feb 21;17:24. Epub 2015 Feb 21.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1186/s13058-015-0538-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374174PMC
February 2015

Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.

Authors:
Charles E Wood Daniel Branstetter Allison P Jacob J Mark Cline Thomas C Register Kathy Rohrbach Li-Ya Huang Hermina Borgerink William C Dougall

Breast Cancer Res 2013 ;15(4):R62

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1186/bcr3456DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978455PMC
December 2014

Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts.

Authors:
Maria Krevvata Barbara C Silva John S Manavalan Marta Galan-Diez Aruna Kode Brya Grace Matthews David Park Chiyuan A Zhang Naomi Galili Thomas L Nickolas David W Dempster William Dougall Julie Teruya-Feldstein Aris N Economides Ivo Kalajzic Azra Raza Ellin Berman Siddhartha Mukherjee Govind Bhagat Stavroula Kousteni

Blood 2014 Oct 18;124(18):2834-46. Epub 2014 Aug 18.

Department of Physiology and Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, NY;

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1182/blood-2013-07-517219DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4314530PMC
October 2014

RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase.

Authors:
Hong Hu Jun Wang Akash Gupta Ali Shidfar Daniel Branstetter Oukseub Lee David Ivancic Megan Sullivan Robert T Chatterton William C Dougall Seema A Khan

Breast Cancer Res Treat 2014 Aug 10;146(3):515-23. Epub 2014 Jul 10.

Department of Surgery, Northwestern University Feinberg School of Medicine, 303 E. Superior Street Lurie 4-111, Chicago, IL, 60611, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10549-014-3049-9DOI Listing
August 2014

RANK expression as a prognostic and predictive marker in breast cancer.

Authors:
Berit Maria Pfitzner Daniel Branstetter Sibylle Loibl Carsten Denkert Bianca Lederer Wolfgang Daniel Schmitt Frank Dombrowski Martin Werner Thomas Rüdiger William C Dougall Gunter von Minckwitz

Breast Cancer Res Treat 2014 Jun 16;145(2):307-15. Epub 2014 Apr 16.

Institute of Pathology, Campus Mitte, Charité University Hospital Berlin, Charitéplatz 1, 10117, Berlin, Germany,

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10549-014-2955-1DOI Listing
June 2014

Targeting RANKL in metastasis.

Authors:
William C Dougall Ingunn Holen Eva González Suárez

Bonekey Rep 2014 9;3:519. Epub 2014 Apr 9.

Cancer Epigenetics and Biology Program PEBC, Bellvitge Institute for Biomedical Research, IDIBELL , Barcelona, Spain.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/bonekey.2014.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4007167PMC
June 2014

RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.

Authors:
Robert E Miller Jon C Jones Mark Tometsko Michelle L Blake William C Dougall

J Thorac Oncol 2014 Mar;9(3):345-54

*Department of Hematology/Oncology Research, Amgen Inc., Seattle, Washington; and †Therapeutic Innovation Unit, Amgen Inc., Seattle, Washington.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0000000000000070DOI Listing
March 2014

RANK expression on breast cancer cells promotes skeletal metastasis.

Authors:
Michelle L Blake Mark Tometsko Robert Miller Jon C Jones William C Dougall

Clin Exp Metastasis 2014 Feb 24;31(2):233-45. Epub 2013 Nov 24.

Oncology Research, Amgen Washington, Seattle, WA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10585-013-9624-3DOI Listing
February 2014

Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis.

Authors:
Pasquale Pellegrini Pellegrini Pasquale Alex Cordero Cordero Alex Marta Ines Gallego Gallego Marta Ines William C Dougall Dougall C William Purificación Muñoz Muñoz Purificación Miguel Angel Pujana Pujana Miguel Angel Eva Gonzalez-Suarez Gonzalez-Suarez Eva

Stem Cells 2013 Sep;31(9):1954-65

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, IDIBELL, Barcelona, Spain.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/stem.1454DOI Listing
September 2013

Progesterone/RANKL is a major regulatory axis in the human breast.

Authors:
Tamara Tanos George Sflomos Pablo C Echeverria Ayyakkannu Ayyanan Maria Gutierrez Jean-Francois Delaloye Wassim Raffoul Maryse Fiche William Dougall Pascal Schneider Ozden Yalcin-Ozuysal Cathrin Brisken

Sci Transl Med 2013 Apr;5(182):182ra55

Swiss Institute for Experimental Cancer Research, National Center of Competence in Research Molecular Oncology, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1126/scitranslmed.3005654DOI Listing
April 2013

RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.

Authors:
Jude Canon Rebecca Bryant Martine Roudier Daniel G Branstetter William C Dougall

Breast Cancer Res Treat 2012 Oct 29;135(3):771-80. Epub 2012 Aug 29.

Department of Oncology Research, Amgen Inc, 1 Amgen Center Drive, Thousand Oaks, CA 91320, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10549-012-2222-2DOI Listing
October 2012

The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.

Authors:
Carsten Goessl Leonid Katz William C Dougall Paul J Kostenuik Holly Brenza Zoog Ada Braun Roger Dansey Rachel B Wagman

Ann N Y Acad Sci 2012 Aug 25;1263:29-40. Epub 2012 Jul 25.

Amgen Inc., Thousand Oaks, California, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1749-6632.2012.06674.xDOI Listing
August 2012

RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis.

Authors:
Marta Palafox Irene Ferrer Pasquale Pellegrini Sergi Vila Sara Hernandez-Ortega Ander Urruticoechea Fina Climent Maria Teresa Soler Purificación Muñoz Francesc Viñals Mark Tometsko Dan Branstetter William C Dougall Eva González-Suárez

Cancer Res 2012 Jun 10;72(11):2879-88. Epub 2012 Apr 10.

Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.

View Article

Download full-text PDF

 Source
http://cancerres.aacrjournals.org/content/early/2012/04/10/0
Web Search
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-12-0044DOI Listing
June 2012

Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.

Authors:
David L Lacey William J Boyle W Scott Simonet Paul J Kostenuik William C Dougall John K Sullivan Javier San Martin Roger Dansey

Nat Rev Drug Discov 2012 May;11(5):401-19

Amgen Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/nrd3705DOI Listing
May 2012

Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.

Authors:
William C Dougall

Clin Cancer Res 2012 Jan 26;18(2):326-35. Epub 2011 Oct 26.

Department of Hematology and Oncology Research, Amgen Inc., Seattle, WA 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2507DOI Listing
January 2012

Combined inhibition of the BMP pathway and the RANK-RANKL axis in a mixed lytic/blastic prostate cancer lesion.

Authors:
Mandeep S Virk Farhang Alaee Frank A Petrigliano Osamu Sugiyama Arion F Chatziioannou David Stout William C Dougall Jay R Lieberman

Bone 2011 Mar 10;48(3):578-87. Epub 2010 Nov 10.

New England Musculoskeletal Institute, Department of Orthopaedic Surgery, University of Connecticut Health Center, Farmington, CT 06030-5456, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bone.2010.11.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3039095PMC
March 2011

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.

Authors:
Eva Gonzalez-Suarez Allison P Jacob Jon Jones Robert Miller Martine P Roudier-Meyer Ryan Erwert Jan Pinkas Dan Branstetter William C Dougall

Nature 2010 Nov 29;468(7320):103-7. Epub 2010 Sep 29.

Department of Hematology/Oncology Research, Amgen Inc, Seattle, Washington 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/nature09495DOI Listing
November 2010

Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis.

Authors:
Jude Canon Rebecca Bryant Martine Roudier Tao Osgood Jon Jones Robert Miller Angela Coxon Robert Radinsky William C Dougall

Bone 2010 Jun 6;46(6):1613-9. Epub 2010 Mar 6.

Department of Oncology Research, Amgen Inc., Thousand Oaks, CA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bone.2010.03.001DOI Listing
June 2010

Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.

Authors:
Pamela M Holland Robert Miller Jon Jones Heather Douangpanya Julia Piasecki Martine Roudier William C Dougall

Cancer Biol Ther 2010 Apr 1;9(7):539-50. Epub 2010 Apr 1.

Department of Oncology, Amgen Inc., Seattle, WA 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.4161/cbt.9.7.11266DOI Listing
April 2010

Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.

Authors:
Paul J Kostenuik Hung Q Nguyen James McCabe Kelly S Warmington Carol Kurahara Ning Sun Ching Chen Luke Li Russ C Cattley Gwyneth Van Shelia Scully Robin Elliott Mario Grisanti Sean Morony Hong Lin Tan Frank Asuncion Xiaodong Li Michael S Ominsky Marina Stolina Denise Dwyer William C Dougall Nessa Hawkins William J Boyle William S Simonet John K Sullivan

J Bone Miner Res 2009 Feb;24(2):182-95

Metabolic Disorders Research, Amgen, Thousand Oaks, California 91320, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1359/jbmr.081112DOI Listing
February 2009

Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.

Authors:
Mandeep S Virk Frank A Petrigliano Nancy Q Liu Arion F Chatziioannou David Stout Christine O Kang William C Dougall Jay R Lieberman

Bone 2009 Jan 26;44(1):160-7. Epub 2008 Sep 26.

Department of Orthopaedic Surgery, The New England Musculoskeletal Institute, University of Connecticut Health Center, Farmington, CT 06030-5456, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.bone.2008.09.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657045PMC
January 2009

RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.

Authors:
Robert E Miller Martine Roudier Jon Jones Allison Armstrong Jude Canon William C Dougall

Mol Cancer Ther 2008 Jul 7;7(7):2160-9. Epub 2008 Jul 7.

Department of Hematology/Oncology Research, Amgen Washington, Seattle, Washington 98119-3105, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0046DOI Listing
July 2008

Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.

Authors:
Jude R Canon Martine Roudier Rebecca Bryant Sean Morony Marina Stolina Paul J Kostenuik William C Dougall

Clin Exp Metastasis 2008 5;25(2):119-29. Epub 2007 Dec 5.

Department of Oncology Research, Amgen Inc., Thousand Oaks, CA, USA.

View Article

Download full-text PDF

 Source
http://link.springer.com/10.1007/s10585-007-9127-1
Publisher Site
http://dx.doi.org/10.1007/s10585-007-9127-1DOI Listing
June 2008

RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

Authors:
G David Roodman William C Dougall

Cancer Treat Rev 2008 Feb 26;34(1):92-101. Epub 2007 Oct 26.

University of Pittsburgh School of Medicine and VA Medical Center, VA Pittsburgh Healthcare System, Research and Development (151-U), Pittsburgh, PA 15240, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ctrv.2007.09.002DOI Listing
February 2008

RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.

Authors:
Allison P Armstrong Robert E Miller Jon C Jones Jian Zhang Evan T Keller William C Dougall

Prostate 2008 Jan;68(1):92-104

Department of Hematology, Amgen Inc., Seattle, Washington 98119, USA.

View Article

Download full-text PDF

 Source
http://deepblue.lib.umich.edu/bitstream/handle/2027.42/57344
Web Search
http://doi.wiley.com/10.1002/pros.20678
Publisher Site
http://dx.doi.org/10.1002/pros.20678DOI Listing
January 2008

RANKL inhibition: from mice to men (and women).

Authors:
Marina Stolina Paul J Kostenuik William C Dougall Lorraine A Fitzpatrick Debra J Zack

Adv Exp Med Biol 2007 ;602:143-50

Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/978-0-387-72009-8_18DOI Listing
December 2007

RANKL signaling in bone physiology and cancer.

Authors:
William C Dougall

Curr Opin Support Palliat Care 2007 Dec;1(4):317-22

Department of Hematology/Oncology Research, Amgen Washington, Seattle, Washington, USA.

View Article

Download full-text PDF

 Source
https://insights.ovid.com/crossref?an=01263393-200712000-000
Publisher Site
http://dx.doi.org/10.1097/SPC.0b013e3282f335beDOI Listing
December 2007

Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.

Authors:
Robert E Miller Daniel Branstetter Allison Armstrong Bryan Kennedy Jon Jones Laine Cowan Jeanine Bussiere William C Dougall

J Immunol 2007 Jul;179(1):266-74

Department of Cancer Biology, Amgen Washington, 1201 Amgen Court West, Seattle, WA 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.4049/jimmunol.179.1.266DOI Listing
July 2007

Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging.

Authors:
Babatunde O Oyajobi Steve Muñoz Rami Kakonen Paul J Williams Anjana Gupta Christi L Wideman Beryl Story Barry Grubbs Allison Armstrong William C Dougall I Ross Garrett Gregory R Mundy

Mol Cancer Ther 2007 Jun 31;6(6):1701-8. Epub 2007 May 31.

Department of Cellular and Structural Biology MSC 7762, University of Texas Health Science Center at San Antonio, Texas 78229-3900, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482358PMC
June 2007

Effects of the RANKL inhibitor, osteoprotegerin, on the pain and histopathology of bone cancer in rats.

Authors:
Martine P Roudier Steven D Bain William C Dougall

Clin Exp Metastasis 2006 16;23(3-4):167-75. Epub 2006 Aug 16.

SkeleTech, Inc., Bothell, WA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10585-006-9026-xDOI Listing
February 2007

RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini.

Authors:
Eva Gonzalez-Suarez Daniel Branstetter Allison Armstrong Huyen Dinh Hal Blumberg William C Dougall

Mol Cell Biol 2007 Feb 4;27(4):1442-54. Epub 2006 Dec 4.

Department of Cancer Biology, AW2/D2262, Amgen Inc., 1201 Amgen Court West, Seattle, WA 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1128/MCB.01298-06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1800710PMC
February 2007

The RANK/RANKL/OPG triad in cancer-induced bone diseases.

Authors:
William C Dougall Michelle Chaisson

Cancer Metastasis Rev 2006 Dec;25(4):541-9

Department of Cancer Biology, Amgen Washington, 1201 Amgen Court West, Seattle, WA 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1007/s10555-006-9021-3DOI Listing
December 2006

Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.

Authors:
Brian T Feeley Nancy Q Liu Augustine H Conduah Lucie Krenek Kevin Roth William C Dougall Johnny Huard Steve Dubinett Jay R Lieberman

J Bone Miner Res 2006 Oct;21(10):1571-80

Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1359/jbmr.060706DOI Listing
October 2006

[Monoclonal antibody targeting RANKL as a therapy for cancer-induced bone diseases].

Authors:
William Dougall Michelle Chaisson

Clin Calcium 2006 Apr;16(4):627- 35

Amgen Inc. Washington, Department of Cancer Biology, Seattle, WA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/CliCa0604627635DOI Listing
April 2006

The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone.

Authors:
Peter G Whang Edward M Schwarz Seth C Gamradt William C Dougall Jay R Lieberman

J Orthop Res 2005 Nov 6;23(6):1475-83. Epub 2005 Jul 6.

Department of Orthopaedic Surgery, David Geffen School of Medicine at UCLA, Center for Health Sciences 76-134, 10833 LeConte Avenue, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.orthres.2005.05.004.1100230634DOI Listing
November 2005

Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.

Authors:
Michelle L Chaisson Daniel G Branstetter Jonathan M Derry Allison P Armstrong Mark E Tometsko Kiyoshi Takeda Shizuo Akira William C Dougall

J Biol Chem 2004 Dec 14;279(52):54841-8. Epub 2004 Oct 14.

Department of Cancer Biology, Amgen Incorporated, Seattle, Washington 98119, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1074/jbc.M406392200DOI Listing
December 2004

Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone.

Authors:
Jian Zhang Jinlu Dai Zhi Yao Yi Lu William Dougall Evan T Keller

Cancer Res 2003 Nov;63(22):7883-90

Department of Pathology, School of Medicine, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0940, USA.

View Article

Download full-text PDF

 Source
November 2003

Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing.

Authors:
Lisa M Flick Jason M Weaver Michael Ulrich-Vinther Faruk Abuzzahab Xinping Zhang William C Dougall Dirk Anderson Regis J O'Keefe Edward M Schwarz

J Orthop Res 2003 Jul;21(4):676-84

Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S0736-0266(03)00011-1DOI Listing
July 2003

The surface antigen CD45R identifies a population of estrogen-regulated murine marrow cells that contain osteoclast precursors.

Authors:
Vedran Katavić Danka Grcević Sun Kyeong Lee Judith Kalinowski Sandra Jastrzebski William Dougall Dirk Anderson Lynn Puddington H Leonardo Aguila Joseph A Lorenzo

Bone 2003 Jun;32(6):581-90

Zagreb University School of Medicine, Zagreb, Croatia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/s8756-3282(03)00097-8DOI Listing
June 2003

A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function.

Authors:
Allison P Armstrong Mark E Tometsko Moira Glaccum Claire L Sutherland David Cosman William C Dougall

J Biol Chem 2002 Nov 15;277(46):44347-56. Epub 2002 Aug 15.

Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1074/jbc.M202009200DOI Listing
November 2002

In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis.

Authors:
Lisa M Childs Eleftherios P Paschalis Lianping Xing William C Dougall Dirk Anderson Adele L Boskey J Edward Puzas Randy N Rosier Regis J O'Keefe Brendan F Boyce Edward M Schwarz

J Bone Miner Res 2002 Feb;17(2):192-9

Department of Microbiology and Immunology, University of Rochester Medical Center, New York 14642, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1359/jbmr.2002.17.2.192DOI Listing
February 2002